- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05193318
KAP for Depression in Abstinent Opioid Users (KReDO)
April 10, 2024 updated by: Eric Dobson, Medical University of South Carolina
Ketamine-assisted Psychotherapy for the Treatment of Persistent Depression in Abstinent Opioid Users
The purpose of the study is to examine whether an investigational medication called ketamine along with psychotherapy is an effective treatment for depression in participants with a history of opioid addiction who have not abused opioids in at least 3 months.
Participants will receive ketamine through intramuscular injection along with psychotherapy weekly for 8 weeks.
Participation for eligible subjects who decide to enroll (including post-medication follow-up visits) will last about 16 weeks or 4 months.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29403
- Medical University of South Carolina Centerspace
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 64 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria
A subject may be eligible for enrollment if all the following inclusion criteria apply within the thirty days prior to first experimental session:
- Between the ages of 18 to 64 years old.
- Able to provide informed consent.
- Meet DSM-5 criteria for Major Depressive Disorder, without psychotic features based on clinical interview.
- Score at least 20 on the Montgomery-Asberg Depression Rating Scale (MADRS, moderate or severe depression).
- Must meet criteria for opioid use disorder in early or sustained remission criteria by DSM-5 based on clinical interview.
- Subjects taking other psychotropic medications (e.g. anti-depressants, anxiolytics, methadone, buprenorphine, naltrexone) must be maintained on a stable dose for at least four weeks before study initiation.
Exclusion Criteria
Subjects will be excluded from the study if any of the following criteria apply:
- They are considered an immediate suicide risk by clinician assessment, self-reports a suicide attempt within the past year, or felt to be likely to require hospitalization during the study.
- Subjects who meet DSM-5 criteria for current bipolar disorder based on clinical interview.
- Subjects who meet DSM-5 criteria for current or history of psychotic spectrum disorders based on clinical interview.
- Subjects meeting DSM-5 criteria for current substance use disorder (i.e., not in early or sustained remission) other than tobacco use disorder.
- Subjects who report use of ketamine >20 times in the past or who meet DSM-5 criteria for Other Hallucinogen Use Disorder due to ketamine use including subjects who are currently in early or sustained remission.
- Women who are pregnant or nursing, and women who do not consent to use methods of highly effective birth control during the interventional phase of the study.
- Subjects with hypertension as defined by a baseline visit systolic blood pressure (SBP) >140 mmHg or a diastolic blood pressure (DBP) >90 mmHg.
- A history of allergic or other adverse reaction to ketamine (or its excipients).
- Clinically significant physical exam findings or self-reported medical conditions for which a transient increase in blood pressure could be significantly detrimental (e.g. glaucoma, aneurysmal disease, cardiovascular disease, or end-stage renal disease).
- QTc will be measured in all subjects and those with QTc 450ms or longer will be excluded.
- Subjects who live greater than 20 miles from the study site and cannot arrange their own transportation will be excluded from the study.
- Subjects with kidney or liver impairment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ketamine-assisted psychotherapy
Subjects will receive 8 weekly intramuscular injections of ketamine hydrochloride starting at 0.5 mg/kg and increasing to a maximum dose of 1.5 mg/kg or a total dose of 60 mg, whichever is lower.
Ketamine administration will be accompanied by psychotherapy before, after and during the session.
|
Subjects will receive 8 weekly intramuscular injections of ketamine hydrochloride starting at 0.5 mg/kg and increasing to a maximum dose of 1.5 mg/kg or a total dose of 60 mg, whichever is lower.
Ketamine administration will be accompanied by psychotherapy before, after and during the session.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Montgomery Asberg Depression Rating Scale
Time Frame: Change from baseline measured at week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, and 16
|
Montgomery Asberg Depression Rating Scale (MADRS).
The MADRS is a clinician administered, 10-item questionnaire of depression severity.
The total score ranges from 0-60, with scores of 0-6 considered normal (non-depressed), 7-19 indicative of mild depression, 20-34 indicative of moderate depression, and 35-60 indicative of severe depression.
Individuals scoring 20 or higher on the MADRS will be included in the study.
The MADRS evaluates the following symptoms of depression: 1) clinical appearance of sadness, 2) self-reported sadness, 3) inner tension, 4) reduced sleep, 5) reduced appetite, 6) concentration difficulties, 7) lassitude, 8) inability to feel, 9) pessimistic thought process, and 10) thoughts of suicide.
Lower scores are better (less depression).
|
Change from baseline measured at week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, and 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Beck Depression Inventory
Time Frame: Change from baseline measured at week 1-9, 10, 12, and 16
|
Self-rated depression inventory; minimum score of 0 maximum score of 63 with lower scores being a better outcome (less depressed)
|
Change from baseline measured at week 1-9, 10, 12, and 16
|
Timeline Follow-back (TLFB)
Time Frame: Measured at week 1-9, 10, 12, and 16
|
Measure of Substance Use; maximum number of substance use days per week is 7 and minimum is 0 with higher number indicating worse outcomes (more substance use)
|
Measured at week 1-9, 10, 12, and 16
|
Visual Analog Scale (VAS)
Time Frame: Change relative to baseline measured at week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, and 16
|
Measure of subjective level of opioid craving; maximum score of 100 and minimum score of 0 with higher scores meaning worse outcome (more cravings)
|
Change relative to baseline measured at week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, and 16
|
Generalized Anxiety Disorder-7 (GAD-7)
Time Frame: Change in score relative to baseline calculated at week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, and 16.
|
Self-report of anxiety symptom severity; minimum score of 0 and maximum score of 21 with higher scores meaning worse outcome (more anxious)
|
Change in score relative to baseline calculated at week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, and 16.
|
Mystical Experience Questionnaire (MEQ)
Time Frame: Measured at week 1-8
|
Measure of perceptual experiences; multiple items rated on a 5 point scale with higher scores indicating more intense perceptual experience.
Total scores are presented as an average (mean) of the 30 item scale, each of which are rated out of 5. Scale is ordered as follows (in reference to magnitude of various perceptual experiences during acute ketamine session): 0 - none; not at all; 1 - so slight cannot decide; 2 - slight; 3- moderate; 4 - strong (equivalent in degree to any other strong experience); 5- extreme (more than any other time in my life and stronger than 4).
|
Measured at week 1-8
|
Brief Pain Inventory (BPI)
Time Frame: Measured at baseline, week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, and 16
|
Measure of pain.
Sub-scale 3 specifically was reported for this outcome.
Subjects were asked: "Please rate your pain by marking the box beside the number that best describes your pain at its worst in the last 24 hours"; maximum score of 10 and minimum of 0 with higher scores indicating worse outcome (more pain) and a score of 0 indicating best outcome (no pain).
|
Measured at baseline, week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, and 16
|
PTSD Checklist (PCL-5; PTSD Checklist 5)
Time Frame: Measured at week 1-9, 10, 12, and 16
|
Measure of PTSD symptoms; maximum score 80 and minimum score of 0 with higher scores indicating worse outcome (more PTSD symptoms)
|
Measured at week 1-9, 10, 12, and 16
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Eric T Dobson, MD, Medical University of South Carolina
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 13, 2022
Primary Completion (Actual)
March 20, 2023
Study Completion (Actual)
March 20, 2023
Study Registration Dates
First Submitted
December 14, 2021
First Submitted That Met QC Criteria
December 30, 2021
First Posted (Actual)
January 14, 2022
Study Record Updates
Last Update Posted (Actual)
May 6, 2024
Last Update Submitted That Met QC Criteria
April 10, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Mood Disorders
- Narcotic-Related Disorders
- Substance-Related Disorders
- Depressive Disorder
- Opioid-Related Disorders
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Ketamine
Other Study ID Numbers
- Pro00115696
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on Ketamine-assisted psychotherapy
-
Chua Yi Rong ShawnNanyang Technological University; Therapeutic and Educational Riding in Singapore...CompletedAggression | Stress | Psychopathy | EmpathySingapore
-
University of New MexicoCompletedPostTraumatic Stress Disorder
-
University of BaselRecruitingMotivation | Alliance, TherapeuticSwitzerland
-
Beckley Med FoundationEnrolling by invitation
-
Universität Duisburg-EssenNot yet recruitingPost Traumatic Stress Disorder
-
University of UtahRecruitingDepression | Anxiety | Gastrointestinal CancerUnited States
-
Field Trip HealthCompletedDepression | Anxiety | Post Traumatic Stress DisorderUnited States, Canada
-
University of Wisconsin, MadisonNot yet recruitingPosttraumatic Stress DisorderUnited States
-
Beersheva Mental Health CenterNot yet recruitingObsessive-compulsive Disorder
-
University of OtagoEnrolling by invitationDepressive Disorder, Treatment-ResistantNew Zealand